Nirsevimab Cuts RSV Hospitalizations in Spanish Study
The introduction of universal passive immunisation with nirsevimab, a long-acting monoclonal antibody, led to significant reductions in hospitalizations and paediatric intensive care admissions for respiratory syncytial virus–associated lower respiratory tract infections (RSV-LRTIs), particularly benefiting infants younger than 6 months.
METHODOLOGY:
Researchers carried out a prospective observational study at a tertiary hospital in Spain to examine if universally administering nirsevimab could reduce hospitalizations and paediatric intensive care admissions due to RSV-LRTIs in children younger than 5 years.
They analysed 311 patients (median age, 4.9 months; 57.5% boys), comparing hospitalization rates during the October 2023-March 2024 RSV season — when nirsevimab was administered — with those during two pre-pandemic seasons (2018-2019 and 2019-2020) and one post-pandemic season (2022-2023).
Nirsevimab immunoprophylaxis was given to all newborns with a gestational age of at least 35 weeks, to infants younger than 6 months, and to high-risk children younger than 2 years.
TAKEAWAY:
RSV-LRTI hospitalizations in infants younger than 6 months declined by 83.3% (95% CI, 70.9-95.8) during the period when nirsevimab was administered compared with those in the pre-pandemic periods and declined by 90.8% (95% CI, 83.6-98.0) compared with those in the post-pandemic period.
Additionally, paediatric intensive care admissions declined by 73.3% during the period when nirsevimab was administered compared with those in the pre-pandemic periods and by 87.9% compared with those in the post-pandemic period.
The median age of hospitalized patients significantly increased during the nirsevimab period, rising to 15.6 months, whereas it was 4 months and 3.4 months in the pre- and post-pandemic periods, respectively ( P < .001).
< .001). Additionally, hospital stays were shorter during the nirsevimab period, with a median of 4 days, whereas they lasted a median of 6 days and 5 days in the pre- and post-pandemic periods, respectively ( P = .003).
IN PRACTICE:
"These findings are encouraging, and it is anticipated that in the coming years, nirsevimab prophylaxis will mitigate the significant burden on healthcare services during the winter season," the authors wrote.
SOURCE:
The study was led by Lorena Bermúdez-Barrezueta, Faculty of Medicine, Valladolid University, Valladolid, Spain. It was published online on May 16, 2025, in the European Journal of Pediatrics .
LIMITATIONS:
This was a single-centre study with a limited sample size.
DISCLOSURES:
The study was supported by FEDER European Funds and the Junta de Castilla y León under the Research and Innovation Strategy for Smart Specialization and partially funded by the Ernesto Sanchez Villares Foundation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Down 80%, Should You Buy the Dip on Moderna?
Moderna stock has dropped along with demand for a product that once drove tremendous growth: the coronavirus vaccine. Investors have remained focused on those declines -- and haven't yet recognized Moderna's long-term potential. 10 stocks we like better than Moderna › A few years ago, Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from drawing board to commercialization in less than a year and saw its stock price skyrocket. The biotech went on to generate billions of dollars in revenue and profit amid soaring demand for its vaccine in those earlier days of the pandemic. But in later stages of the health crisis, fewer people rushed to get vaccinated, and this had a significant impact on Moderna's earnings -- and stock performance. Though Moderna has since won approval for updated versions of its vaccine and approval for another respiratory shot and the company has cut costs, the earnings and stock performance path remain difficult. But there are reasons to be optimistic about Moderna's long-term prospects as it has a robust late-stage pipeline ready to potentially deliver several products. Considering the full picture, down 80% over the past year, is Moderna a buy? Let's find out. So, as mentioned, Moderna was a brilliant success story just a few years ago. The company even proved the safety and efficacy of a new technology based on messenger RNA. This is important because it's a technology Moderna uses throughout its pipeline. The company's mRNA technique involves teaching the body to produce a particular protein that will protect it from or help it fight a virus or disease. Considering the depth of the pandemic, regulators helped speed coronavirus vaccines to the finish line, but it's worth keeping in mind that these products were based on years of research. Now, of course, investors have to be more patient and wait longer for Moderna's products to earn a regulatory nod because they aren't being approved for an early pandemic situation. As a result, Moderna right now continues to generate most of its revenue from the coronavirus vaccine, and it also brings in revenue from sales of its respiratory syncytial virus (RSV) vaccine, approved last year. Unfortunately for Moderna and its investors, however, coronavirus vaccine sales have declined, and the RSV vaccine hasn't performed as well as initially expected. But before throwing in the towel on Moderna, it's key to remember that better days are likely down the road. The company is at a point of transition right now as it prepares for what could be a great number of product launches ahead. In fact, Moderna recently reiterated it may roll out as many as 10 new products within the next few years. These products represent a total addressable market of $30 billion, so this could offer revenue a major boost. These programs also span many indications, from cytomegalovirus to oncology -- this is positive because Moderna won't depend on just one or two treatment areas in the future, reducing risk if one product sees a slowdown. It's also important to note that there's less risk of a slowdown when treating an ever-present virus or disease versus dealing with a pandemic situation -- pandemics result in steep gains, but when the situation improves, sales may sharply drop off. Meanwhile, Moderna has progressed nicely on its cost cutting program, and beyond this year, plans to reduce as much as $1.7 billion in estimated GAAP operating costs by 2027. Now let's return to our question: After Moderna's 80% drop, is the stock a buy? Moderna still faces challenges ahead. For example, the company recently lost U.S. government funding for its investigational bird flu vaccine, and uncertainty about the policies of President Trump's administration on vaccines could add to headwinds. On top of this, investors still often view Moderna as a COVID vaccine company and focus on declines in demand for that product. These elements could weigh on the stock's performance. But for investors who don't mind some volatility and plan on holding on to the stock for at least five years, Moderna makes an exciting biotech buy right now. If the company even partially reaches its product launch goal, the long-term revenue picture could look very bright. Before you buy stock in Moderna, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Moderna wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. Down 80%, Should You Buy the Dip on Moderna? was originally published by The Motley Fool
Bloomberg
an hour ago
- Bloomberg
Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill
By and Steven T. Dennis Save Senate Republicans are considering cuts to Medicare spending to help pay for Donald Trump's signature legislative package. The GOP lawmakers are proceeding cautiously as they expand their search for savings to a popular health insurance program nearly all Americans rely upon in retirement, presenting the move as an effort to root out waste, fraud and abuse. That includes cutting payments to health insurance companies that run private Medicare plans.
Forbes
2 hours ago
- Forbes
U.S. Seniors Nearly Double Cannabis Use In Just Two Years, Study Finds
U.S. Seniors are turning to cannabis more than ever, with use nearly doubling in the past two years, a new study shows. Published this week in JAMA Internal Medicine, four researchers from the University of California and NYU Langone Health found that monthly cannabis use among adults aged 65 and older increased from 4.8% in 2021 to 7% in 2023, resulting in a 45.83% increase. The reasons for this increase are attributed to several factors, including greater access to cannabis. As of today, medical cannabis is legal in 39 states and Washington D.C., while 24 states have also legalized it for recreational use. The situation was slightly different in 2021, when medical cannabis was legal in 36 states and recreational use was legal in 17 states. In 2021, New York, Virginia, New Mexico, and Connecticut legalized cannabis for recreational use. The rise in access to cannabis, both medical and recreational, helps explain why more older adults are using it, especially as more people become aware of medical programs and the health issues cannabis can help treat. This cross-sectional study analyzed 15,689 adults aged 65 and older using data from the National Survey on Drug Use and Health (NSDUH), a nationwide survey of people in the U.S. who aren't living in institutions. The findings show that, between 2021 and 2023, cannabis use among older adults in the U.S. saw a significant rise, with some groups showing especially sharp increases. People with a college or postgraduate degree, for example, went from 4.9% to 8.3% in cannabis use. Among those earning $75,000 or more, cannabis use more than doubled, from 4.2% to 9.1%. Married adults also showed a big jump, going from 3.8% to 7.4%. Older adults living in states where medical cannabis is legal were more likely to use it, and that number kept climbing from 5.4% to 7.9%. 'It shouldn't be surprising that use is becoming increasingly more common among people who live in states that allow medical cannabis, which could be due to increased availability or social acceptability,' said Joseph Palamar, the study's senior author in a press statement, adding that 'with respect to income, those with the highest incomes had the lowest prevalence of cannabis use in 2021, but by 2023 this group had the highest prevalence, which may indicate who has access to medical cannabis given its costs.' The most dramatic increase came from people with chronic obstructive pulmonary disease (COPD), whose usage doubled from 6.4% to 13.5%. People with chronic conditions like cancer, diabetes, heart disease, and high blood pressure also reported using cannabis more. And those dealing with two or more chronic illnesses saw use rise from 3.5% to 8.2%. The authors of this study concluded that these findings show a real shift in how older adults are using cannabis, especially those living with chronic illnesses, and that people with multiple health conditions were more likely to use it. However, they also highlighted that 'the use of cannabis products, especially with psychoactive properties, may complicate chronic disease management among older adults.' These new findings line up with what earlier studies have shown. Back in 2020, a study published in the same journal looked at data from nearly 15,000 adults over 65 using the same national survey and found that cannabis use among older adults had already been on the rise for years, jumping from just 0.4% in 2006 and 2007 to 2.9% by 2015 and 2016. In recent years, researchers have also started to study how long-term cannabis use affects older adults. For example, a study published last year suggested that taking low doses of THC over time may not only help protect the brain from aging but also boost memory, improve cognitive function, and support seniors's overall well-being and longevity. This likely has to do with a key cellular pathway called mTOR, which is a protein that helps control how cells use energy and build new connections in the brain, which are important for learning and memory.
